EUCTR2014-005303-24-BE进行中（未招募）1 期
A Multicenter, Long-term, Open-label Study to Evaluate the Safety of MT10109L (NivobotulinumtoxinA) for the Treatment of Glabellar Lines and Lateral Canthal Lines
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Medytox Inc
- 入组人数
- 800
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •- Completion of lead-in Phase 3 study: Study MT10109L-001 for GL participants, Study MT10109L-002 for LCL participants, Studies MT10109L-005 or-006 for GL and LCL participants.
- •- Stable medical condition, in the opinion of the investigator
- •- Female participants willing to minimize the risk of inducing pregnancy for the duration of the clinical study and follow-up period
- •- Female participants of childbearing potential must have a negative urine pregnancy test before each study intervention. A female is considered NOT to be of childbearing potential if she is premenarchal, postmenopausal (at least 12 consecutive months without menstruation), or permanently sterilized (eg, tubal occlusion, hysterectomy, bilateral oophorectomy).
- •- Capable of giving signed informed consent as described in Appendix 1, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol
- •- Written informed consent from the participant has been obtained prior to any study-related procedures.
- •- Written documentation has been obtained in accordance with the relevant country and local privacy requirements, where applicable (eg, Written Authorization for Use and Release of Health and Research Study Information [US sites] and written Data Protection consent [EU sites])
- •- Ability to follow study instructions, including completing study assessment tools without any assistance or alteration to the assessment tools and likely to complete all required visits
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 760
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 40
排除标准
- •- Known immunization or hypersensitivity to any botulinum toxin serotype
- •- Any medical condition that may put the participant at increased risk with exposure to MT10109L including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere with neuromuscular function
- •- Any brow or eyelid ptosis, as determined by the investigator
- •- Infection or skin disorder at the injection sites
- •- Any uncontrolled systemic disease
- •- Recent history of alcohol or drug abuse based on the investigator’s judgement
- •- Anticipated need for treatment with botulinum toxin of any serotype for any reason during the study (other than study intervention)
- •- Anticipated need for surgery or overnight hospitalization during the study
- •- Known allergy or sensitivity to any of the components of the study interventions, or any materials used in the study procedures
- •- Current enrollment in an investigational drug or device study or participation in such a study within 30 days of entry into this study, except the prior qualifying lead-in Phase 3 study
- •- Females who are pregnant, nursing, or planning a pregnancy during the study. Females of childbearing potential, not using a reliable means of contraception.
- •- Participants who plan for an extended absence away from the immediate area of the study site that would preclude them from returning for all protocol-specified study visits
- •- Participants who, in the investigator’s opinion, are unable or unwilling to maintain their standardized skin care regimen throughout the study period
- •- The participant has a condition or is in a situation which, in the investigator’s opinion, may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant’s participation in the study.
研究者
相似试验
进行中（未招募）
1 期
MT10109L in the Long-term, Open-label Treatment of Glabellar Lines and Lateral Canthal LinesGlabellar Lines & Lateral Canthal LinesMedDRA version: 21.1Level: LLTClassification code 10052609Term: Glabellar frown linesSystem Organ Class: 100000004858EUCTR2014-005303-24-DEMedytox Inc800
未知
4 期
A Multicenter, Open-Label, Long-Term Study to Evaluate the Efficacy and Safety of LY2439821 in Japanese Patients with Moderate-to-Severe PsoriasisPsoriasisJPRN-jRCT2080221846Eli Lilly Japan K.K.
未知
3 期
A Multicenter, Open-Label, Long-Term Study to Evaluate the Safety and Efficacy of OVF in Patients With Cancer and Breakthrough PaiCancer pain (breakthrough pain)JPRN-jRCT2080220447Taiho Pharmaceutical Co., Ltd.
已完成
4 期
A Clinical Trial to evaluate the safety and Tolerability of Treatment in Adolscent patients with Schizophrenia.CTRI/2012/09/002953Otsuka Pharmaceutical Development and Commercialization Inc250
进行中（未招募）
不适用
An open label study assessing safety and tolerability of aripirazole in Adolescent Patients with Schizophrenia or Child and Adolescent Patients with Bipolar I Disorder.Schizophrenia in Adolescent Patients or Child and Adolescent Patients with Bipolar I Disorder, Manic or Mixed Episode with or without Psychotic FeaturesMedDRA version: 14.1Level: PTClassification code 10039626Term: SchizophreniaSystem Organ Class: 10037175 - Psychiatric disordersMedDRA version: 14.1Level: PTClassification code 10004939Term: Bipolar I disorderSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2010-018911-13-PLOtsuka Pharmaceutical Development & Commercialization, Inc.300